These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 24683168)

  • 1. Assessment of relapse in patients with peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using F-18-FDG-PET/CT.
    Klumpp B; Schwenzer NF; Gatidis S; Koenigsrainer I; Koenigsrainer A; Beckert S; Mueller M; Claussen CD; Pfannenberg C
    Rofo; 2014 Apr; 186(4):359-66. PubMed ID: 24683168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative assessment of peritoneal carcinomatosis in patients undergoing hyperthermic intraperitoneal chemotherapy following cytoreductive surgery.
    Pasqual EM; Bertozzi S; Bacchetti S; Londero AP; Basso SM; Santeufemia DA; Lo Re G; Lumachi F
    Anticancer Res; 2014 May; 34(5):2363-8. PubMed ID: 24778044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Pfannenberg C; Königsrainer I; Aschoff P; Oksüz MO; Zieker D; Beckert S; Symons S; Nieselt K; Glatzle J; Weyhern CV; Brücher BL; Claussen CD; Königsrainer A
    Ann Surg Oncol; 2009 May; 16(5):1295-303. PubMed ID: 19252950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of FDG-PET/CT for peritoneal carcinomatosis before hyperthermic intraperitoneal chemotherapy.
    Berthelot C; Morel O; Girault S; Verrièle V; Poirier AL; Moroch J; Boucher Y; Le Jeune JJ; Lorimier G
    Nucl Med Commun; 2011 Jan; 32(1):23-9. PubMed ID: 21042225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pitfalls and mimickers on (18)F-FDG-PET/CT in peritoneal carcinomatosis from colorectal cancer: An analysis from 37 patients.
    Audollent R; Eveno C; Dohan A; Sarda L; Jouvin I; Soyer P; Pocard M
    J Visc Surg; 2015 Nov; 152(5):285-91. PubMed ID: 26115889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reply to: Use of FDG PET/CT for peritoneal carcinomatosis before hyperthermic intraperitoneal chemotherapy: some considerations.
    Campos PA; Gil J; Parrilla P
    Nucl Med Commun; 2011 May; 32(5):421. PubMed ID: 21467875
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical Value of (18)F-FDG- PET-CT in the Preoperative Staging of Peritoneal Carcinomatosis from Colorectal Origin.
    De Vos N; Goethals I; Ceelen W
    Acta Chir Belg; 2014; 114(6):370-5. PubMed ID: 26021680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI.
    Klumpp BD; Schwenzer N; Aschoff P; Miller S; Kramer U; Claussen CD; Bruecher B; Koenigsrainer A; Pfannenberg C
    Abdom Imaging; 2013 Feb; 38(1):64-71. PubMed ID: 22476333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
    Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
    Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent thyroid cancer diagnosis: ROC study of the effect of a high-resolution head and neck 18F-FDG PET/CT scan.
    Chatziioannou SN; Georgakopoulos AT; Pianou NK; Kafiri GT; Pavlou SN; Kallergi M
    Acad Radiol; 2014 Jan; 21(1):58-63. PubMed ID: 24331265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
    Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
    Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of (18)F-FDG PET/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue.
    Lopez-Lopez V; Cascales-Campos PA; Gil J; Frutos L; Andrade RJ; Fuster-Quiñonero M; Feliciangeli E; Gil E; Parrilla P
    Eur J Radiol; 2016 Oct; 85(10):1824-1828. PubMed ID: 27666623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of contrast-enhanced CT combined with 18-FDG PET in patients selected for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Sommariva A; Evangelista L; Pintacuda G; Cervino AR; Ramondo G; Rossi CR
    Abdom Radiol (NY); 2018 May; 43(5):1094-1100. PubMed ID: 28770289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (18)F-FDG PET/CT, cytoreductive surgery and intraperitoneal chemohyperthermia for the therapeutic management in peritoneal carcinomatosis: A pilot study.
    Cistaro A; Cucinotta M; Cassalia L; Priola A; Priola S; Pappalardo M; Coppolino P; De Simone M; Quartuccio N
    Rev Esp Med Nucl Imagen Mol; 2016; 35(4):232-7. PubMed ID: 26907833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT.
    Dirisamer A; Schima W; Heinisch M; Weber M; Lehner HP; Haller J; Langsteger W
    Eur J Radiol; 2009 Mar; 69(3):536-41. PubMed ID: 18248928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer.
    Strobel K; Heinrich S; Bhure U; Soyka J; Veit-Haibach P; Pestalozzi BC; Clavien PA; Hany TF
    J Nucl Med; 2008 Sep; 49(9):1408-13. PubMed ID: 18703604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
    Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
    Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.